Sodium Hyaluronate
2 organisations hold 2 active FDA Type IV Drug Master Files for Sodium Hyaluronate. 2 further filings are inactive and shown as history. 49 valid EDQM Certificates of Suitability are on record for the same substance.
Sources: FDA List of Drug Master Files (checked 13 Nov 2026); FDA Global Substance Registration System (identity); EDQM Certification Online Database. Methodology
Active Type IV DMFs (2)
| Holder | DMF | Filed as | Submitted |
|---|---|---|---|
| MUBY CHEM PRIVATE LTD India | 41115 | SODIUM HYALURONATE BP | Apr 2025 |
| ANMOL CHEMICALS PRIVATE LTD | 40916 | SODIUM HYALURONATE BP | Dec 2024 |
“Filed as” is the subject exactly as the holder gave it to the FDA, including the grade or pharmacopoeia it names. Holder names link to a company profile where one is published. An active filing can be referenced by a drug application; it is not proof of current supply.
Valid CEPs for this substance (49)
| Holder | Country | Certificate | Issued |
|---|---|---|---|
| Altergon Italia | IT | CEP 2014-263 - Rev 02 Sodium hyaluronate, Intrinsic viscosity 0.2-3.2 m3/kg, by fermentation, for parenteral administration including intra-articular administration and intra-ocular use | Oct 2026 |
| Altergon Italia | IT | CEP 2026-262 - Rev 00 Sodium hyaluronate, Intrinsic viscosity 0.8 m3/kg, 1.4 m3/kg, 1.8 m3/kg, 2.4 m3/kg; by fermentation; for parenteral administration other than intra-articular administration | Sept 2026 |
| AMHWA BIOPHARM CO LTD | CN | CEP 2021-235 - Rev 02 Sodium hyaluronate, Intrinsic viscosity: 2.93 m3/kg, from fermentation, for parenteral administration, including intra-articular administration, and for intra-ocular use | Aug 2026 |
| AMHWA BIOPHARM CO LTD | CN | CEP 2021-234 - Rev 02 Sodium hyaluronate, Intrinsic viscosity 2.12 m3/kg, from fermentation, for parenteral administration, including intra-articular administration, and for intra-ocular use | Aug 2026 |
| CONTIPRO AS | CZ | CEP 2003-194 - Rev 04 Sodium hyaluronate, Intrinsic viscosity: not less than 0.65 m3/kg; by fermentation, for parenteral administration including intra-articular use and intra-ocular use | Jul 2026 |
| KIKKOMAN BIOCHEMIFA CO | JP | CEP 2016-247 - Rev 01 Sodium hyaluronate, Grade 80; intrinsic viscosity 1.70 m3/kg; from fermentation, for parenteral administration, including intra-ocular use | Jun 2026 |
| KEWPIE CORP | JP | CEP 2025-641 - Rev 00 Sodium hyaluronate, HYALURONASAN HA-SHL 150: Intrinsic viscosity 2.00 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | May 2026 |
| SHANDONG FOCUSFREDA BIOTECH CO LTD | CN | CEP 2025-464 - Rev 00 Sodium hyaluronate, Intrinsic viscosity 3.0 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | May 2026 |
| KIKKOMAN BIOCHEMIFA CO | JP | CEP 2020-420 - Rev 01 Sodium hyaluronate, GS-100, intrinsic viscosity: 1.50 m3/kg; from fermentation; for parenteral administration, including intra-ocular use | Dec 2025 |
| AMHWA BIOPHARM CO LTD | CN | CEP 2018-285 - Rev 02 Sodium hyaluronate, Intrinsic viscosity 1.55 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | Sept 2025 |
| MARUHA NICHIRO CORP | JP | CEP 2007-242 - Rev 02 Sodium hyaluronate, Intrinsic viscosity: 1.62m3/kg - 1.70m3/kg and 2.28m3/kg - 3.78m3/kg; from fermentation; for parenteral administration, including intra-articular administration and intra-ocular use | Aug 2025 |
| KIKKOMAN BIOCHEMIFA CO | JP | CEP 2020-138 - Rev 01 Sodium hyaluronate, GS-200; intrinsic viscosity 2.77 m3/kg; from fermentation; for parenteral administration, including intra-ocular use | Jul 2025 |
| KEWPIE CORP | JP | CEP 2019-064 - Rev 01 Sodium hyaluronate, Intrinsic viscosity 2.93 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | Jul 2025 |
| KIKKOMAN BIOCHEMIFA CO | JP | CEP 2023-034 - Rev 02 Sodium hyaluronate, GS-120, intrinsic viscosity: 1.7 m3/kg; from fermentation; for parenteral administration, including intra-ocular use | Apr 2025 |
| KEWPIE CORP | JP | CEP 2018-037 - Rev 03 Sodium hyaluronate, Intrinsic viscosity 1.28 m3/kg; 1.63 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | Mar 2025 |
| SHANDONG FOCUSFREDA BIOTECH CO LTD | CN | CEP 2021-388 - Rev 01 Sodium hyaluronate, Intrinsic viscosity 2.3 m3/kg, by fermentation, for parenteral administration other than intra-articular administration and intra-ocular use | Feb 2025 |
| CONTIPRO AS | CZ | CEP 2024-332 - Rev 00 Sodium hyaluronate, Intrinsic viscosity: 2.50 m3/kg; by fermentation; for non-parenteral use | Dec 2024 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | CEP 2010-290 - Rev 04 Sodium hyaluronate, HA-EP 3.0 (intrinsic viscosity: 2.7-3.6 m3/kg); from fermentation; for parenteral administration including intra-articular administration and intra-ocular use | Jul 2024 |
| HTL | FR | CEP 2012-335 - Rev 03 Sodium hyaluronate, Alternative process; Intrinsic viscosity : less than 1.8 m3/kg, by fermentation, for parenteral and ophthalmic administration including intra-articular use and intra-ocular use | Jul 2024 |
| HTL | FR | CEP 2001-385 - Rev 09 Sodium hyaluronate, Intrinsic viscosity: 1.7 m3/kg, 1.9 m3/kg, 2.4 m3/kg, 2.8 m3/kg, or 3.5 m3/kg, by fermentation, for parenteral administration including intra-articular use and intra-ocular use | Jul 2024 |
| HTL | FR | CEP 2004-238 - Rev 06 Sodium hyaluronate, Intrinsic viscosity 0.2 to 2.4 m3/kg; by fermentation; for parenteral administration and for intra-ocular and intra-articular use | Jul 2024 |
| KIKKOMAN BIOCHEMIFA CO | JP | CEP 2022-341 - Rev 00 Sodium hyaluronate, GS-300, intrinsic viscosity: 3.8 m3/kg; from fermentation; for parenteral administration, including intra-ocular use | Jul 2024 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | CEP 2021-220 - Rev 02 Sodium hyaluronate, Intrinsic viscosity 1.8 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | Jun 2024 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | CEP 2017-195 - Rev 01 Sodium hyaluronate, Intrinsic viscosity 2.5 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | May 2024 |
| Fidia Farmaceutici S.p.A. | IT | CEP 2017-220 - Rev 01 Sodium hyaluronate, Intrinsic viscosity: 0.5 m3/kg; 1.25 m3/kg; 2.0 m3/kg; 2.67 m3/kg; from fermentation; for cutaneous and parenteral administration, including intra-articular administration, and for intra-ocular use. | Apr 2024 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | CEP 2015-200 - Rev 01 Sodium hyaluronate, HA-E2.0 (intrinsic viscosity 1.2-2.8 m3/kg), from fermentation, for parenteral administration other than intra-articular administration and intra-ocular use | Mar 2024 |
| Altergon Italia | IT | CEP 2014-263 - Rev 01 Sodium hyaluronate, Intrinsic viscosity 0.2-3.2 m3/kg, by fermentation, for parenteral administration including intra-articular administration and intra-ocular use | Mar 2024 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | CEP 2018-107 - Rev 04 Sodium hyaluronate, Intrinsic viscosity 2.4 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | Feb 2024 |
| LIFECORE BIOMEDICAL LLC | US | CEP 2021-250 - Rev 00 Sodium hyaluronate, Intrinsic viscosity 3.4 m3/kg, by fermentation, sterile, for intra-ocular use | Oct 2023 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | CEP 2010-289 - Rev 04 Sodium hyaluronate, HA-EP 1.8 (intrinsic viscosity: 1.6-2.2 m3/kg); from fermentation; for parenteral administration including intra-articular administration and intra-ocular use | Sept 2023 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | R0-CEP 2021-446 - Rev 01 Sodium hyaluronate, Intrinsic viscosity 0.6 m3/kg and 0.8 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | Jun 2023 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | R0-CEP 2022-129 - Rev 01 Sodium hyaluronate, Intrinsic viscosity 3.8 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | May 2023 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | R1-CEP 2016-172 - Rev 00 Sodium hyaluronate, Intrinsic viscosity 1.4 m3/kg and 1.0 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | May 2023 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | R0-CEP 2021-258 - Rev 02 Sodium hyaluronate, Intrinsic viscosity 1.25 m3/kg, by fermentation, for parenteral administration including intra-articular administration and for intra-ocular use | Mar 2023 |
| Fidia Farmaceutici S.p.A. | IT | R0-CEP 2023-001 - Rev 00 Sodium hyaluronate, Intrinsic viscosity: 0.5 m3/kg; 0.83 m3/kg and 1.25 m3/kg; from fermentation; for cutaneous and parenteral administration, including intra-articular administration, and for intra-ocular use. | Feb 2023 |
| SHANDONG TOPSCIENCE BIOTECH CO LTD | CN | R0-CEP 2022-269 - Rev 00 Sodium hyaluronate, intrinsic viscosity 1.66 m3/kg, 2.27 m3/kg, 3.30 m3/kg; from fermentation; for parenteral administration including intra-articular administration and intra-ocular use | Jan 2023 |
| AMHWA BIOPHARM CO LTD | CN | R0-CEP 2021-235 - Rev 01 Sodium hyaluronate, Intrinsic viscosity: 2.93 m3/kg, from fermentation, for parenteral administration, including intra-articular administration, and for intra-ocular use | Jun 2022 |
| SHANDONG TOPSCIENCE BIOTECH CO LTD | CN | R1-CEP 2013-348 - Rev 01 Sodium hyaluronate, SH 2.2; intrinsic viscosity 2.2 m3/kg, from fermentation; for parenteral administration including intra-articular administration and intra-ocular use | May 2022 |
| SHANDONG TOPSCIENCE BIOTECH CO LTD | CN | R1-CEP 2015-261 - Rev 01 Sodium hyaluronate, SH 1.3; intrinsic viscosity 1.3 m3/kg, from fermentation; for parenteral administration including intra-articular administration and intra-ocular use | May 2022 |
| SHANDONG TOPSCIENCE BIOTECH CO LTD | CN | R1-CEP 2013-349 - Rev 01 Sodium hyaluronate, SH 3.0; intrinsic viscosity 3.0 m3/kg, from fermentation; for parenteral administration including intra-articular administration and intra-ocular use | Mar 2022 |
| Fidia Farmaceutici S.p.A. | IT | R0-CEP 2021-428 - Rev 00 Sodium hyaluronate, Intrinsic viscosity: 1.6 m3/kg; 2.0 m3/kg and 2.5 m3/kg; from fermentation; for cutaneous and parenteral administration, including intra-articular administration, and for intra-ocular use. | Feb 2022 |
| BLOOMAGE BIOTECHNOLOGY CORP., LTD. Jinan CN | CN | R1-CEP 2015-201 - Rev 00 Sodium hyaluronate, HA-E3.0 (intrinsic viscosity 2.7-3.6 m3/kg), from fermentation, for parenteral administration other than intra-articular administration and intra-ocular use | Nov 2021 |
| LIFECORE BIOMEDICAL LLC | US | R1-CEP 2004-285 - Rev 05 Sodium hyaluronate, Intrinsic viscosity ranges: 0.3-0.9 m3/kg, 1.0-2.3 m3/kg and 1.8-3.1 m3/kg; by fermentation; for parenteral administration and for intra-ocular and intra-articular use after appropriate sterilisation | Mar 2021 |
| CONTIPRO AS | CZ | R1-CEP 2010-330 - Rev 01 Sodium hyaluronate, Type II (intrinsic viscosity: not higher than 0.70 m3/kg), from fermentation, for parenteral administration including intra-articular administration and intra-ocular use | Oct 2017 |
| Fidia Farmaceutici S.p.A. | IT | R1-CEP 2009-015 - Rev 01 Sodium hyaluronate, Intrinsic viscosity: 2.0-3.4 m3/kg, from fermentation; for parenteral administration, including intra-articular administration, and for intra-ocular use | Jun 2015 |
| Bio-Technology General (Israel) Ltd. Kiryat Malachi IL | IL | R1-CEP 2002-243 - Rev 00 Sodium hyaluronate, Intrinsic viscosity 2.7-3.6 m3/kg, by fermentation, for parenteral administration including intra-articular and intra-ocular use | Jul 2010 |
| Fidia Farmaceutici S.p.A. | IT | R1-CEP 2001-249 - Rev 02 Sodium hyaluronate, Intrinsic viscosity: 1.0-1.5 m3/kg, by fermentation, for intra-articular use | Oct 2009 |
| Fidia Farmaceutici S.p.A. | IT | R1-CEP 2001-250 - Rev 01 Sodium hyaluronate, Intrinsic viscosity: 0.3 - 0.6 m3/kg, by fermentation, for cutaneous use | Oct 2008 |
| Fidia Farmaceutici S.p.A. | IT | R1-CEP 2001-248 - Rev 01 Sodium hyaluronate, Intrinsic viscosity: 1.7-2.1 m3/kg, by fermentation, for intra-ocular use | Jul 2008 |
Certification Online Database, European Directorate for the Quality of Medicines & HealthCare. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.
Inactive filings (2)
- KYOWA HAKKO KOGYO CO LTD · SODIUM HYALURONATEDMF 11366 · Feb 1995
- QP CORP · SODIUM HYALURONATEDMF 10091 · Feb 1993
Inactive filings are closed or lapsed and cannot be referenced. They are shown as history only.
What these records establish
- A Type IV DMF is a confidential file held by the FDA for an excipient, colourant or flavour. The FDA does not approve or disapprove it; it is reviewed when a drug application references it.
- Active means the file is open and can be referenced with the holder's letter of authorisation. It says nothing about price, capacity or current availability.
- The holder is the organisation that filed. It is usually, but not always, the manufacturer.
- Many excipients are supplied without any DMF, so this list is not every supplier of Sodium Hyaluronate.
Do you supply Sodium Hyaluronate?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.